How we have helped
How we
have helped
At MSD we have dedicated teams to support NHS Trusts to tackle challenges in relation to managing current and future patient demand for treatment, and to manage cancer pathways in the most efficient ways possible.
Explore our previous work below where we have collaborated with NHS Trusts to support NHS staff and enhance the patient experience within Oncology.
LUNG > FULL PATHWAY > SOUTH EAST
Oxford Respiratory Early Diagnosis Service (REDS)
MSD supported to reduce the lung cancer pathway by an average of 16 days.
LUNG > FULL PATHWAY > EAST MIDLANDS
Nottingham University Hospital NHS Trust
An improvement of the 28-day FDS, the 2WW and 31-day treatment target.
LUNG > 28 DAY > SOUTH WEST
Peninsula Cancer Alliance
See how we supported a reduction in lung patient breaches of the 28-day FDS across three hospitals.
PAN TUMOUR > MULTIDISIPLINARY TEAM > NORTH WEST
Greater Manchester Multidisciplinary Team (MDT) Reform
See how we supported the implementation of the Greater Manchester MDT standards and reform toolkit.
LUNG > PREHABILITATION > SOUTH WEST
Gloucestershire AHP Prehabilitation Service (GAPS)
See how we helped to demonstrate the outcomes of the prehabilitation service.
LUNG > PATHOLOGY > NORTHERN IRELAND
Belfast Health and Social Care Trust
Improvements to a faster diagnostic pathway across pathology, radiology and more.
PAN TUMOUR > PREHABILITATION > SOUTH WEST
SWAG Cancer Alliance Prehabilitation Patient Information Platform
See how we aided the development of a digital cancer prehabilitation platform for patients, caregivers and healthcare professionals.
PAN TUMOUR > PATHOLOGY > NORTH WEST
Blackpool Teaching Hospitals NHS Foundation Trust Diagnostic PDP
See how we supported the reduction in pan-tumour histopathology pathway turnaround times.
PAN TUMOUR > PATHOLOGY > NORTH EAST
South Yorkshire & Bassetlaw Histopathology PDP
See how we supported a reduction in Cancer Wait Times through enhancements to the pan-tumour pathology testing pathway.
PAN TUMOUR > DIAGNOSIS > NORTH WEST
Clatterbridge Cancers of Primary Unknown Diagnostic PDP
See how we supported the optimisation of the genomic testing pathway and fostered collaboration to reduce turnaround times.
The above projects (including the Pathway Development Programmes) have been carried out under collaborative working agreements between MSD and the NHS. For further information on all collaborative working projects that MSD undertake, please visit Collaborative Working – MSD UK (msd-uk.com)
Driving health equity in cancer: Practical examples from Cancer Alliances
Case examples addressing the underlying issues of inequalities in health, access to care, and interaction with NHS services.
Enhancing Multidisciplinary Team (MDT) Meetings
Highlighting opportunities for cancer patient outcomes through collaboration and improving the quality and efficiency of MDT meetings.
National Capacity
Meeting 2024
Catch up on the meeting and find out more about how challenges in cancer pathways can be overcome
Get in touch
Talk to one of the team about challenges you’re facing and find out how we can help
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000).
Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
GB-NON-11186 | Date of Preparation: April 2025
Hide Footer
